Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Research & Development (2018 - 2026)

10x Genomics' Research & Development history spans 8 years, with the latest figure at $56.0 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 16.42% to $56.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $238.6 million, a 9.85% decrease, with the full-year FY2025 number at $238.6 million, down 9.85% from a year prior.
  • Research & Development hit $56.0 million in Q4 2025 for 10x Genomics, down from $57.2 million in the prior quarter.
  • Over the last five years, Research & Development for TXG hit a ceiling of $71.5 million in Q2 2023 and a floor of $41.9 million in Q1 2021.
  • Historically, Research & Development has averaged $62.6 million across 5 years, with a median of $64.2 million in 2022.
  • Biggest five-year swings in Research & Development: surged 93.94% in 2021 and later decreased 16.42% in 2025.
  • Tracing TXG's Research & Development over 5 years: stood at $61.9 million in 2021, then increased by 2.79% to $63.6 million in 2022, then grew by 2.6% to $65.3 million in 2023, then increased by 2.61% to $67.0 million in 2024, then fell by 16.42% to $56.0 million in 2025.
  • Business Quant data shows Research & Development for TXG at $56.0 million in Q4 2025, $57.2 million in Q3 2025, and $61.2 million in Q2 2025.